Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;47(12):2234-2241.
doi: 10.1111/ced.15384. Epub 2022 Oct 28.

Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis

Fernando Valenzuela  1   2 , Claudia De La Cruz  3 , Cristóbal Lecaros  4 , Javier Fernández  2 , Gonzalo Hevia  4 , Lara Valeska Maul  5 , Jacob P Thyssen  6   7 , Cristián Vera-Kellet  8 , Alexander Egeberg  6   7 , Daniela Armijo  3 , Cristian Pizarro  9 , Tatiana Riveros  4 , Hernán Correa  10   11 , Antonio Guglielmetti  12 , Johannes A Didaskalu  13 , Jashin J Wu  14 , Christopher E M Griffiths  15   16 , Ricardo Romiti  17 , Julia-Tatjana Maul  13   18
Affiliations

Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis

Fernando Valenzuela et al. Clin Exp Dermatol. 2022 Dec.

Abstract

Background: Psoriasis is a chronic inflammatory skin disease associated with several important medical comorbidities. There are scant data available on the comorbidities of patients with psoriasis in South America.

Aim: To examine the comorbidity profile of adult patients with psoriasis in Chile and its association with severity of psoriasis.

Methods: This was a multicentre, cross-sectional study involving 16 hospitals and clinics in Chile, which used a 48-item questionnaire to study clinician- and patient-reported outcomes and comorbidities. Inferential analyses were performed by psoriasis severity, using Fisher exact test, Student t-test and multivariable logistic regression.

Results: In total, 598 adult patients with psoriasis were included (51.1% male; mean age 49.2 ± 15.1 years); 48.5% mild and 51.4% moderate to severe; Psoriasis Area and Severity Index 11.6 ± 11.5; body surface area 14.7 ± 18.2%. Plaque psoriasis was the most common phenotype (90.2%), followed by guttate (13.4%). Psoriatic arthritis occurred in 27.3% of patients. Comorbidities were reported in 60.2% of all patients with psoriasis. Frequent concomitant diseases were obesity (25.3%), hypertension (24.3%), Type 2 diabetes mellitus (T2DM) (18.7%), dyslipidaemia (17.4%), metabolic syndrome (16.7%) and depression (14.4%). After adjustment, significant associations were found between moderate to severe psoriasis and obesity, T2DM and nonalcoholic fatty liver disease (NAFLD) compared with mild psoriasis.

Conclusions: We report a large study of comorbidities, including depression, dyslipidaemia, T2DM and NAFLD, in people with psoriasis in Chile. The prevalence of comorbidities with psoriasis in Chile appears similar to that found in Western countries, and emphasizes the importance of assessing patients with psoriasis for risk factors for and presence of, comorbid disease in a multidisciplinary setting.

PubMed Disclaimer

Conflict of interest statement

FV has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Amgen, Eli Lilly, LEO Pharma, Janssen‐Cilag, Novartis, Pfizer and Sanofi. CDLC has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Amgen, Boehringer‐Ingelheim, Bristol Myers Squibb, Coherus, Eli Lilly, Genentech, Janssen‐Cilag, Novartis, Pfizer, Sanofi and UCB. CL has participated in clinical trials sponsored by Sanofi, Pfizer and Novartis. JF has participated in clinical trials sponsored by Pfizer and Novartis. DA has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Janssen‐Cilag and LEO Pharma. CP has participated in clinical trials sponsored by SANOFI Genzyme and Novartis. HC has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by Serono, Novartis and Galderma. AG has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Janssen‐Cilag, Novartis and Pfizer. CEMG has received honoraria and/or research funding from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Janssen‐Cilag, LEO Pharma, Novartis, Pfizer and UCB. RR has served as a scientific consultant, speaker or clinical study investigator for AbbVie, Boehringer Ingelheim, Galderma, Janssen‐Cilag, Eli‐Lilly, Leo‐Pharma, Novartis, Pfizer, TEVA and UCB. JTM has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly, LEO Pharma, Janssen‐Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi and UCB. LVM has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by Almirall, Amgen, BMS, Celgene, Eli Lilly, MSD, Novartis, Pierre Fabre, Roche and Sanofi. JJW is or has been an investigator, consultant or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, DermTech, Dr Reddy's Laboratories, Eli Lilly, EPI Health, Galderma, Janssen, LEO Pharma, Mindera, Novartis, Pfizer, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB and Zerigo Health. JPT is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi‐Genzyme; a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi‐Genzyme; and received research grants from Pfizer, Regeneron and Sanofi‐Genzyme. AE has received research funding from Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation; and has received honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd. Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co. Ltd. Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol‐Myers Squibb and Janssen Pharmaceuticals. The remaining authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
(a,b) Clinical characteristics of the study population. (a) The diagram shows the different types of psoriasis, the main one corresponding to plaque followed by guttate. The other type corresponds to pustular, palmoplantar and erythrodermic subtypes. (b) There were no differences in the severity of psoriasis among the different health insurance mechanisms. PASI, Psoriasis Area Severity Index.
Figure 2
Figure 2
Forest plot of odds ratios for presenting moderate to severe psoriasis by the presence of different comorbidities. For example, the presence of Type 2 diabetes increases the odds of moderate to severe psoriasis in 85% of patients (OR = 1.85, 95% CI 1.02–3.40, P = 0.04).
See this image and copyright information in PMC

References

    1. Griffiths CEM, Jo S‐J, Naldi L et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol 2018; 179: 173–81. - PubMed
    1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet 2021; 397: 1301–15. - PubMed
    1. Takeshita J, Grewal S, Langan SM et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017; 76: 377–90. - PMC - PubMed
    1. Dauden E, Blasco AJ, Bonanad C et al. Position statement for the management of comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2018; 32: 2058–73. - PubMed
    1. Radtke MA, Mrowietz U, Feuerhahn J et al. Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis. J Dtsch Dermatol Ges 2015; 13: 674–90. - PubMed